Morgan Stanley Assumes BeiGene, Ltd. (BGNE) at Overweight

Morgan Stanley analyst Sean Laaman assumes coverage on BeiGene, Ltd. (NASDAQ: BGNE) with a Overweight rating and a price target of $300.00.

The analyst comments "Superior safety and efficacy of BGNE's 2nd gen BTKi, Brukinsa, continues to drive its market share growth. Brukinsa's developing EU presence is underappreciated by Street revenue estimates. Emerging data could suggest LLY's 3rd gen BTKi, Jaypirca remains 2nd line to Brukinsa, though 1L data is due Q125. BGB-16683 (BTK degrader), a key pipeline asset, provides some insurance to future market disruption. Sonrotoclax (BCL2 inhibitor) is potentially best in class and a combo with Brukinsa could be compelling."

For an analyst ratings summary and ratings history on BeiGene, Ltd. click here. For more ratings news on BeiGene, Ltd. click here.

Shares of BeiGene, Ltd. closed at $205.75 yesterday.

You May Also Be Interested In

• Bernstein SocGen Group Starts Terawulf Inc. (WULF) at Outperform
• RBC Capital on Veeva Systems (VEEV) Amid After Hours Selloff on Earnings: 'we are surprised to see shares trade down'
• Bernstein SocGen Group Starts Cipher Mining (CIFR) at Outperform